Successful MDR Certification for AI Solution in Predicting Postoperative Complications – New Product Generation for Optimized Patient Safety
Berlin, October 2, 2024
x-cardiac, a leader in AI-based medical devices for the prediction of postoperative complications after cardiac surgery, is pleased to announce the successful MDR (Medical Device Regulation) certification of its new x-cardiac-platform. This certification introduces a completely new generation of products offering state-of-the-art technologies to optimize patient care and safety.
The x-cardiac-platform is an innovative tool in the field of digital biomarkers and is specifically designed to increase patient safety and treatment quality in critical situations. With the successful MDR certification, the platform fulfills the strictest European requirements for safety and performance and thus marks a significant milestone in medical technology.
The new product generation includes two innovative plug-ins: x-c-bleeding and x-c-renal-injury. These plug-ins offer unprecedented support in the detection and treatment of bleeding and kidney damage after major heart surgery.
“With the new product generation, we can offer completely new possibilities for predicting postoperative complications in everyday clinical practice, which we will now increasingly promote beyond Germany, Austria, and Switzerland, also with sales partners,” says Oliver Höppner, CEO of x-cardiac. “With the x-cardiac platform, we are offering users a powerful medical device that can make a lasting difference in patient care. We are looking forward to the upcoming EACTS Annual Summit 2024 (European Association for Cardio-Thoracic Surgery) from October 10-12 in Lisbon, where we plan to present our new product generation to the professional audience.”
Chief Medical Officer Prof. Dr. Alexander Meyer on the new product generation: “The x-cardiac-platform sets new standards in the clinical care of patients by performing local validation of the algorithms for each customer. This enables us to ensure that our solutions are optimally tailored to individual needs and circumstances. Optional fine tuning allows us to customize the models to deliver even more precise results.”
Contacts
Oliver Höppner
x-cardiac GmbH
presse@xcardiac.com
www.xcardiac.com
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Vorwerk Group Continues Global Expansion in Direct Sales8.11.2024 08:28:52 CET | Pressmeddelande
Strategic invests in Australia, New Zealand, Malaysia and Singapore
Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain7.11.2024 11:04:10 CET | Press Release
The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures[1], thus affecting more than 3 million people with surgical procedures per year in the U.S.[2] QUTENZA® is a topical system, non-systemic, non-opioid pain treatment that is currently approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. Topline results are expected in Q4 2025 and Averitas Pharma aims to submit a supplemental new drug application (sNDA) for a US label extension in 2026, subject to positive data.
Pioneering women set the stage for Slush at the INNOVEIT Conference in Helsinki5.11.2024 09:55:00 CET | Press Release
The European Institute of Innovation and Technology (EIT) invites you to celebrate women entrepreneurs driving innovation and investment in Europe. The EIT Community will be hosting the INNOVEIT Conference which will feature industry leaders like Inga Grieger, Katarzyna Piasecki and Laura Wirsztel. A pitch session will showcase pioneering women-led ventures shaping the future of technology. Exclusive insights: Conference attendees will gain access to the latest research findings from the study “Women founders in European deep tech startups” by the initiative EIT Supernovas, revealing women’s impact in deep tech and the launch of the new Data Room which enhances visibility for women-led startups and scaleups by connecting them with potential investors.
HEIDELBERG develops the AI-controlled print shop of tomorrow4.11.2024 09:00:00 CET | Pressmeddelande
20 years of applied digitalization and 5 years of experience with AI HEIDELBERG has been networking machines and systems in print shops since 2004 13,000 units worldwide are connected to the HEIDELBERG Cloud Three-digit million euro amount for digital processes, products and services
Competition is on for the CIVIS Media Prize 2025: Submissions possible until 12 December 202431.10.2024 10:30:00 CET | Press Release
31.10.2024 – Köln (ots) | The competition for the European CIVIS Media Prize is on. Until 12 December 2024, media professionals from all EU countries and Switzerland can submit entries online on the topics of migration, integration, cultural diversity and related issues of social cohesion. The CIVIS Media Prize honours outstanding achievements in television, radio, internet and social media that promote the peaceful coexistence of people from different geographical and cultural backgrounds. It is endowed with a total of 27,000 euros. Nine CIVIS AWARDS are awarded in various categories. Further information on the CIVIS Media Prize 2025 can be found here. Click here to register. The CIVIS Media Prize is sponsored by ARD, represented by WDR, together with the Freudenberg Foundation. ORF, SRG SSR, ARTE, 3sat, Deutsche Welle, Deutschlandradio and EBU are media partners. WDR mediagroup, the Allianz Deutscher Produzentinnen und Produzenten – Film, TV und Audiovisuelle Medien e.V., the Verwert
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom